Experts in the production and differentiation of iPSCs

Newcells Biotech is serving the biotech and pharma industries across the UK and Europe

News from Newcells

Newcells Biotech to develop a new skin metabolism model using iPSC derived skin cells

NEWCASTLE UPON TYNE, UK, 26th April 2016

Newcells Biotech has been successful in partnering with Newcastle University to receive funding in a 100K phase I NC3R CRACK IT project to develop a new skin metabolism model using iPSC derived skin cells.

Working with academics Prof Mark Birch-Machin and Dr Peter Hanson from the Institute of Cellular Medicine, Newcells is using its expertise in cellular reprogramming and differentiation of iPSCs to provide cells that will be used to construct a new skin model that will enable understanding of skin metabolism of topical drugs and xenobiotics. The project titled Metaboderm was one of only three in the UK that received funding under the scheme and the project is sponsored by GSK, Unilever, Stiefel and Dstl.

Newcells Biotech Ltd completes a licensing agreement with iPS Academia Japan, Inc. for induced pluripotent stem cell technologies

NEWCASTLE UPON TYNE, UK, 9th September 2015

Newcells Biotech Ltd has signed a patent license agreement with iPS Academia Japan, Inc. to license and commercialise Kyoto University’s patented technologies in the field of induced pluripotent stem cells (iPSC’s).

The agreement will enable Newcells Biotech to develop, manufacture, distribute products and offer services to customers in the pharmaceutical, biotechnology and academic sectors in Europe. Newcells Biotech, based in Newcastle upon Tyne UK, offers a range of iPSC derived differentiated cells to drug discovery and development teams including neural progenitor cells, cardiomyocytes, haematopoietic progenitors and retinal pigmented epithelium. Complementing these off-the-shelf products the company offers a reprogramming and differentiation service that enables customers the option of an outsourced quality source of cells for their discovery programmes.

Dr Mike Nicholds CEO of Newcells Biotech commented on the signing of the license:

“The discovery of IPSC’s in 2006 was a landmark event in the history of stem cell biology. Since that time the uptake of iSPC technology by academe and industry has accelerated with numerous applications in the fields of pre-clinical drug development. By completing this agreement Newcells Biotech can apply the scientific expertise of its co-founders to assist our customers to develop new disease modelling approaches and screening assays that are based on a source of reliable differentiated human cells produced at scale.”

The patents related to iPS cell technologies licensed by iPS Academia Japan are the result of the break-through research of Professor Shinya Yamanaka of the Center for iPS Cell Research and Application (CiRA) at Kyoto University, Japan. iPSC’s bear enormous potential for the elucidation of pathogenesis through disease modelling and the development of therapeutic strategies. Somatic cells can be induced into iPSC’s by introduction of nuclear reprogramming factors, which iPSC’s can subsequently be differentiated into specific cell types of diverse lineages, making it possible to develop cell lines for, among other applications, screening potential treatments at the patient level. This approach, owing to its personalized nature, ensures greater predictive accuracy in disease modelling and treatment outcome.

About Newcells Biotech Ltd

Newcells Biotech Ltd is a spinout from Newcastle University based on the IP of the scientific co-founders Prof Lyle Armstrong and Prof Majlinda Lako who have an extensive academic track record in stem cell biology and the applications of iPSC’s. The team at Newcastle have successfully produced over 700 human iPSC cell lines and a range of differentiated cells from healthy donors and patients. The expertise and infrastructure in the company offers a centre of expertise that works collaboratively with customers to develop new applications in pre-clinical discovery and development.

About iPS Academia Japan, Inc.

iPS Academia Japan, Inc. (AJ) is an affiliate of Kyoto University, and its main role is to manage and utilize the patents and other intellectual properties held/controlled by Kyoto University and other institutions in the field of iPS cell technologies so that the research results contribute to health and welfare worldwide. AJ was established in Kyoto in June 2008. AJ's patent portfolio consists of approximately 110 patent families (350 patent application cases) in iPS cell technologies as of July 2015, and approximately 150 license arrangements have been executed with domestic or international entities. For more information, visit www.ips-cell.net.

Newcells Biotech Ltd Completes a Licensing Agreement with ID Pharma Co., Ltd for Induced Pluripotent Stem Cell technologies

NEWCASTLE UPON TYNE, UK, 28th September 2015

Newcells Biotech Ltd has signed a patent license agreement with ID Pharma Co., Ltd to license and commercialise ID Pharma Co., Ltd patented technologies in the Sendai virus vectors for reprogramming cells to induced pluripotent stem cells (iPSCs).

The agreement will enable Newcells Biotech to develop, manufacture, distribute products and offer services to customers based on reprogramming cells using the CytioTuneTM-iPS kit. Newcells Biotech, based in Newcastle upon Tyne UK, offers a range of iPSC derived differentiated cells to drug discovery and development teams including neural progenitor cells, cardiomyocytes, haematopoietic progenitors and retinal pigmented epithelium. Complementing these off-the-shelf products the company offers a reprogramming and differentiation service that enables customers the option of an outsourced quality source of cells for their discovery programmes.

Prof Lyle Armstrong CSO of Newcells Biotech commented on the signing of the license:

“We carried out an extensive evaluation of a number of reprogramming technologies before adopting the CytoTuneTM system. In our hands this method of reprogramming human somatic cells to IPSCs gives us the most reliable and efficient results. Using this technology we have successfully produced over 700 iPSC lines from a range of samples including skin fibroblasts, blood and keratinocytes, all with full virus clearance.”

Sendai virus vector (SeV vector) is a vector based on the novel concept “Cytoplasmic RNA vector” that ID Pharma has successfully brought into practical use for the first time in the world. Its applications include a wide range of important bio-businesses such as gene therapy, gene vaccine, therapeutic antibody production, gene function analysis, and recombinant protein production.

About Newcells Biotech Ltd

Newcells Biotech Ltd is a spinout from Newcastle University based on the IP of the scientific co-founders Prof Lyle Armstrong and Prof Majlinda Lako who have an extensive academic track record in stem cell biology and the applications of iPSC’s. The team at Newcastle have successfully produced over 700 human iPSC cell lines and a range of differentiated cells from healthy donors and patients. The expertise and infrastructure in the company offers a centre of expertise that works collaboratively with customers to develop new applications in pre-clinical discovery and development.

About ID Pharma Co., Ltd

ID Pharma Co., Ltd successfully developed an innovative vector system, which is expected to be an indispensable device for gene therapy, gene vaccine and cell therapy etc. Sendai virus vector is one such vector which does not cause any chromosomal damage to the host cells. The company has developed a kit (CytoTuneTM-iPS) for reprogramming of somatic cells based on the Sendai vector technology. ID Pharma sells CytoTuneTM-iPS for research use in Japan and overseas. In addition, ID Pharma has increased the number of license grants to companies worldwide who supply/sell iPS cells and differentiated cells derived from iPS cells for research purposes. ID Pharma now envisions expanding the application of CytoTuneTM-iPS to clinical fields.

If you want to discuss your iPSC project please call us or contact us at enquiries@newcellsbiotech.co.uk.

Newcells Biotech Limited
Biomedicine West
International Centre for Life, Times Square
Newcastle upon Tyne, NE1 4EP, UK

Tel: +44 (0)191 241 8695
Email: enquiries@newcellsbiotech.co.uk

 

Newcells Biotech Limited is registered in England, company number: 09389592

Newcells Biotech Limited 2015